Serascience Limited

Company description

Serascience develops products to improve the diagnosis of patients with certain cancers (myeloma).

SeraScience is an immunodiagnostic company focused on the development of rapid diagnostic and monitoring immunoassays for haematological malignancies, SeraScience was acquired by Abingdon Health Limited in 2014.

Serascience Limited is a specialist cancer diagnostic company established in April 2011 to develop medical devices for the diagnosis and management of patients with myeloma and related disorders, collectively known as B-cell dyscrasias. Our innovative products will improve patient management through better diagnostic and prognostic assessment. Serascience supply a broad range of class and subclass specific anti immunoglobulin antibodies, for research use. We offer unique, highly specific, quality antibodies at a competitive price. Our catalogue includes monoclonal antibodies for all immunoglobulins classes, and a number of subclasses, as well as antibodies to the heavy and light chains of immunoglobulins. These antibodies can be used for an array of applications and assays, such as WB (Western blots), ELISAs (Enzyme-linked immunosorbent assays), IP (Immuneprecipitation), IHC (Immunohistochemistry), ICC (Immunocytochemistry), and flow cytometry.

Project impact

In Oct 2014, Abingdon Health, the specialist rapid diagnostic technology company, announced the acquisition of Serascience Limited and the completion of group fund-raising of £2.1m from current shareholders. The acquisition represents a further development in Abingdon Health's strategy to create a leading innovative global diagnostic company. This follows on from a project joint funded by CiC and Serascience, and a move by the postdoc working on this project, from UoB to Serascience.

The lead diagnostic SeraLite is currently being used within the NHS for the diagnosis and management of patients with myeloma.